24/7 Wall Street
19 Jul 2026, 13:30 UTC · 15h ago
3 Biggest Pharma Giants: Buy, Sell or Hold?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
19 Jul 2026, 13:30 UTC · 15h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
One predictive model implies a 30.9% downside for AbbVie (ABBV) to $168.67 due to a trailing P/E of 122 and negative book value. — A significant projected price drop backed by extreme valuation metrics suggests high risk of a correction.
-0.60Eli Lilly (LLY) reported Q1 2026 revenue growth of 55.5% to $19.80B, with Mounjaro and Zepbound accounting for 64.7% of total revenue. — Exceptional growth and strong demand for GLP-1 drugs provide a powerful bullish fundamental driver.
+0.50Johnson & Johnson (JNJ) raised 2026 guidance to $100.3B–$101.3B in sales with accelerating revenue growth reaching 9.9% in Q1 2026. — Guidance raises and accelerating growth indicate strong operational momentum and potential for further rerating.
+0.40Continue reading
6 related stories
Top 3 movers · tap to explore
Eli Lilly's stock appears fully valued after a 421% five-year run, with prediction-market sentiment slipping 21.4 points over 30 days. — While fundamentals are strong, deteriorating sentiment and high valuation limit immediate upside potential.
-0.30J&J faces litigation charges of $330M in Q1 and an upcoming Enterprise Business Review on December 8, 2026. — Litigation and corporate reviews are known volatility catalysts that can create short-term price swings.
-0.20Which stocks this story touches
Described as the most compelling buy on fundamentals with accelerating revenue growth and consecutive EPS beats.
Faces a stretched valuation, negative book value, and a predictive model suggesting significant downside.
Strong financial results and drug growth are offset by a high valuation that suggests patience for new investors.
Mentioned only as a historical success story for a stock picking service.
Mentioned only as a historical success story for a stock picking service.
Mentioned only as a historical success story for a stock picking service.
[mutual] Both are identified as the biggest US pharma names by market cap and are compared based on valuation and performance.
[mutual] Both are identified as the biggest US pharma names by market cap and are compared based on valuation and performance.
[mutual] Both are identified as the biggest US pharma names by market cap and are compared based on valuation and performance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
The Motley Fool
6h ago
